• 1. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 2. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 3. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139

Introduction to 2-(4-ethylcyclohexyl)morpholine (CAS No. 2228300-76-1)

2-(4-ethylcyclohexyl)morpholine, identified by the Chemical Abstracts Service Number (CAS No.) 2228300-76-1, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the morpholine class, characterized by a six-membered aromatic ring containing an oxygen atom and a morpholine moiety. The presence of an ethyl-substituted cyclohexyl group at the 4-position introduces unique structural and functional properties, making it a valuable candidate for various chemical and biological applications.

The synthesis of 2-(4-ethylcyclohexyl)morpholine involves multi-step organic reactions, typically starting from cyclohexanone or its derivatives. The introduction of the ethylcyclohexyl group is achieved through alkylation or Friedel-Crafts reactions, followed by nucleophilic substitution to incorporate the morpholine ring. This synthetic pathway highlights the compound's versatility in medicinal chemistry, where structural modifications can significantly influence its pharmacological activity.

Recent advancements in drug discovery have positioned 2-(4-ethylcyclohexyl)morpholine as a promising intermediate in the development of novel therapeutic agents. Its morpholine core is known for its ability to enhance solubility and bioavailability, critical factors in drug formulation. Moreover, the ethylcyclohexyl substituent may contribute to improved metabolic stability, reducing the likelihood of rapid degradation in vivo. These attributes make it an attractive scaffold for designing small-molecule drugs targeting various diseases.

In the realm of medicinal chemistry, 2-(4-ethylcyclohexyl)morpholine has been explored for its potential role in modulating biological pathways associated with inflammation, pain, and neurodegenerative disorders. Preclinical studies have demonstrated its efficacy in inhibiting certain enzymes and receptors, suggesting therapeutic benefits comparable to existing morpholine-based drugs but with improved pharmacokinetic profiles. For instance, derivatives of this compound have shown promise in reducing interleukin-6 (IL-6) production, a key cytokine involved in inflammatory responses.

The pharmacological activity of 2-(4-ethylcyclohexyl)morpholine is further enhanced by its ability to interact with biological targets through hydrogen bonding and hydrophobic interactions. The morpholine ring's oxygen atom serves as a hydrogen bond acceptor, while the ethylcyclohexyl group provides a hydrophobic surface that can penetrate lipid bilayers effectively. This dual interaction mechanism is crucial for achieving high binding affinity and prolonged residence time at target sites.

Recent research has also highlighted the compound's potential in oncology. Studies indicate that 2-(4-ethylcyclohexyl)morpholine derivatives can inhibit tyrosine kinases involved in cancer cell proliferation and survival. By binding to these kinases' active sites, the compound disrupts signaling pathways that promote tumor growth, offering a novel approach to cancer therapy. Additionally, its ability to cross the blood-brain barrier suggests potential applications in treating central nervous system (CNS) tumors and neuroinflammatory diseases.

The chemical stability of 2-(4-ethylcyclohexyl)morpholine under various conditions has been thoroughly investigated to ensure its suitability for industrial-scale production and pharmaceutical applications. Analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and high-performance liquid chromatography (HPLC) have been employed to confirm its structural integrity and purity. These studies have revealed that the compound remains stable under controlled storage conditions but may degrade when exposed to extreme temperatures or acidic environments.

In industrial applications, 2-(4-ethylcyclohexyl)morpholine serves as a key intermediate in synthesizing more complex molecules used in agrochemicals and specialty chemicals. Its morpholine moiety is particularly valuable in designing herbicides and fungicides that exhibit enhanced environmental compatibility while maintaining high efficacy against pests and pathogens. This aligns with global trends toward sustainable agriculture practices that minimize ecological impact.

The safety profile of 2-(4-ethylcyclohexyl)morpholine has been evaluated through toxicological studies conducted on cell cultures and animal models. Preliminary results suggest low toxicity at therapeutic doses, with minimal side effects observed even at higher concentrations. However, further research is necessary to fully understand its long-term safety implications before human clinical trials can commence. These studies are crucial for ensuring patient safety while advancing drug development efforts.

The future prospects of 2-(4-ethylcyclohexyl)morpholine are bright, with ongoing research exploring new synthetic methodologies and applications. Innovations in computational chemistry and artificial intelligence are accelerating the discovery of novel derivatives with enhanced pharmacological properties. Collaborative efforts between academia and industry are expected to yield breakthroughs that could revolutionize therapeutic approaches across multiple medical disciplines.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)